

Judith M Bliss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1416914/publications.pdf>

Version: 2024-02-01

11
papers

353
citations

1936888

4
h-index

1473754

9
g-index

16
all docs

16
docs citations

16
times ranked

544
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mini-MAC. <i>Journal of Psychosocial Oncology</i> , 1994, 12, 33-46.	0.6	312
2	The MARS feasibility trial: conclusions not supported by data – Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 1094-1095.	5.1	26
3	Quality of life after breast radiotherapy – Authors' reply. <i>Lancet Oncology</i> , The, 2010, 11, 612-613.	5.1	5
4	10 Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests. <i>Annals of Oncology</i> , 2021, 32, S21-S22.	0.6	4
5	0186 Treatment options for locally advanced or metastatic triple negative breast cancer: A survey of current UK practice. <i>Breast</i> , 2009, 18, S65.	0.9	1
6	SP-0314: Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. <i>Radiotherapy and Oncology</i> , 2017, 123, S162-S163.	0.3	1
7	OC-0156: Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. <i>Radiotherapy and Oncology</i> , 2018, 127, S79.	0.3	1
8	Exemestane or tamoxifen? – Authors' reply. <i>Lancet</i> , The, 2007, 369, 1600-1601.	6.3	0
9	P.18 Adjuvant Cytotoxic Chemotherapy In Older Women (ACTION). <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, S41.	2.0	0
10	99P Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome. <i>Annals of Oncology</i> , 2021, 32, S65-S66.	0.6	0
11	815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI). <i>Annals of Oncology</i> , 2021, 32, S768.	0.6	0